Strains for the day: a trade label that is not supported by its genome

Does any study indicate strains for the day?

None. No clinical work has been published that compares the strain described as daytime with another in terms of alertness or performance during the day. The three available studies focus on the genetics and chemistry of the plant, not the patient, and all three challenge the very division from which this label arises. Below is what was measured in them.

A 2021 study in Nature Plants compared chemical labels with the genotype of the same plants. With over one hundred thousand checked polymorphic sites, the boundary between material described as sativa and material described as indica did not appear at all. The labels came from suppliers, the samples were not randomized, so this is a picture of the market, not an experiment with random assignment.

The other two studies approach the same issue from a different angle. The analysis of commercial samples from six U.S. states found reproducible chemical groups, but trade names only partially adhered to them. Older genotyping of over fourteen thousand sites yielded moderate, not zero, consistency, and that is how we describe it here.

No study has been published to verify whether the strain described as daytime actually impairs alertness or performance during the day less than any other. The division into daytime and nighttime strains is not a clinically studied category, but a commercial description derived from the pair sativa and indica, and this pair does not genetically separate plants. The label is at most associated with terpene composition, and no one has measured the effect of this composition on human alertness.

Where did the pair sativa and indica come from?

From trade and horticulture, not from patient studies. The pair described the plant's morphology and geographical origin, and only later was the promise of stimulation or relaxation added. The genetics of these two do not confirm: the declared origin explains the structure of strains only moderately, as shown by the 2015 genotyping (PMID:26308334).

The same study yielded a result that shows how loose the label can be. Hemp for fiber genetically clustered closer to indica-type plants than to sativa-type plants. Material grown for fiber has nothing to do with the time of day, yet it lands on one side of the division by which the market describes the expected effect.

We mention the limitations of this study along with its result. It genotyped 14,031 polymorphic sites in 43 samples of hemp and 81 samples of psychoactive cannabis, thus using conveniently collected, not randomly collected material, and with a density lower than in newer analyses. The consistency labeled as moderate is not any consistency, and it should not be taken away from it.

Newer data do not change anything here. When material with both labels was compared on a genome-wide scale, there was nothing to separate, and the difference between the plants lay elsewhere, in several volatile compounds.

What strain characteristics can be measured here at all?

Volatile composition and chemotype, that is, what can be seen in the analysis of a sample. The label was associated in the 2021 study with the content of several terpenes, and their concentration is determined by genetic variants in clusters of genes coding for terpene synthases. This is where the measurable trace of the label ends.

The trace is narrow and does not lead to the patient. The content of compounds in the plant was measured, not alertness in humans, and there is no study standing between the two. Adding a promise of stimulation to the volatile profile would be a conclusion that no one has verified, although it sounds credible.

We describe individual terpenes separately, along with what is unknown about them: terpinolen, limonene and myrcene. None of these pages assigns a time of day to the compound, as such measurement does not exist in humans.

Analysis of commercial samples from six U.S. states showed that repeatable chemical groups truly exist. The problem is not chemistry, but the assignment of names: some labels lean towards one chemotype more often than would be expected by chance, but never exclusively (PMID:35588111).

Does the strain name predict the composition of a specific batch?

It does not predict it bindingly. The authors of the commercial sample analysis state directly that the adopted nomenclature can be detached from the chemistry of the material it is supposed to describe. The name carries information about the breeder and the batch, not a guarantee of consistent composition in the next delivery. The pharmacy register describes the position, not the plant.

Previous genotyping reached a consistent conclusion from the genomic side: strain names often do not designate a distinct genetic identity, so two batches under one label can be different plants. The authors do not claim that names are worthless; they assert that they do not have the power attributed to them.

For a patient in Poland, this has practical consequences. The pharmacy position is identified by the registration name along with the manufacturer, not by an adjective from the store description. We maintain a current list of these positions in the list of available strains, as the market composition changes faster than the content of the article.

The practical conclusion is modest and is meant to be so. The same name from two manufacturers can be two separate registration positions, with separately studied compositions, and the coincidence of names does not constitute proof of material similarity. What remains verifiable is what the manufacturer declared for a given series and what the analysis of that series showed, and only on this can anything be based.

What does the doctor decide, and what does the patient decide?

The choice of raw material is determined by the attending physician. Dried flower is issued in Poland solely by a doctor's prescription in the Rpw category, so the daily label is not a selection criterion available to the patient in the store. The patient provides observations: the time of intake, tolerance, symptoms, and these return to the doctor as material for decision-making.

The doctor weighs factors that no label contains: diagnosis, previous treatment, a list of other preparations, and the route of administration. The trade name enters this conversation at most as a shorthand that the patient uses to describe previous experience, and it is read that way.

This page does not indicate any position or any manufacturer and does not suggest what to replace the doctor's decision with. We describe only what follows from three studies on the plant, and what does not follow from them. Dried flower is a pharmaceutical raw material issued by a doctor's prescription in the Rpw category, and advertising medicinal products issued on prescription directed to public knowledge is prohibited.

The division of roles is often confused when the store text presents a label as a suggestion. The commercial description does not have the status of information about a medicinal product; such a role is fulfilled by the product characteristics and the leaflet, which the doctor and pharmacist refer to. The difference is not a formality, as it determines whose knowledge is responsible for the consequences.

How quickly does dried flower start to work and how long does it last?

It depends on the route of administration, not on whether the strain is called daily. The difference between inhaling vapor and swallowing can reach hours and is greater than any difference between cultivars described in available studies. The following description thus pertains to the route of administration, and we read it that way.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

What adverse effects have been described in studies on daytime strains?

None. The three studies on which this page is based examined plant material, not patients, so they did not collect reports of symptoms. Therefore, there is no separate compilation of adverse effects for strains described as daytime, as there is also no clinical study that would isolate such a group.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

It is also not possible to provide frequencies separately for material described as daytime, as reports do not have such a category. The trade label does not enter the documentation of the registration position, so even if someone collected a complete set of data, they would not have a way to separate the daytime group from the rest of the dried flower.

What remains of the daily label when you subtract its promise?

What remains is the commercial description and a narrow chemical trace. The label can be a shorthand for the seller, useful in conversation, but it does not describe either the plant's genome or the human reaction. Everything that can be said about the position from the documents is in its register, not in the adjective attached to the name.

The second half of the same label has a separate text about odmianach na noc, where there is also a meta-analysis regarding sleep. On the daytime side, there is no equivalent of such work, and that is the most important difference between the two halves of the division.

The availability of pharmaceutical products changes from month to month, as it depends on approvals and wholesale supplies, and besides, it is hindered by the retail section with dried flower without a prescription. A description that can be verified lists the manufacturer, the registered name, and the tested composition, not the time of day.

Instead of an adjective, there remains documentation: batch number, manufacturer, declared content of active substances, and the results of the profile analysis, if the manufacturer has provided such results. This is material that is less rich than the promise of the time of day, but verifiable, and the distance between the two is precisely the subject of this page.

Frequently Asked Questions

Is a sativa strain a daytime strain?

Not in a verifiable sense. Samples labeled as sativa and samples labeled as indica did not separate in the whole genome analysis, so the label itself does not define a group of plants with different effects.

Does the daytime label result from the terpene profile?

Partially. The label was associated with the content of several terpenes, which are determined by genetic variants in clusters of genes coding for terpene synthases. However, no one has verified whether this difference translates into alertness in humans.

Does the strain name guarantee the same composition in every delivery?

No. In commercial samples, repeatable chemotypes can be distinguished, but sales names do not consistently correspond to them, and the relationship is often more frequent than random, but never exclusive.

Who decides on the choice of strain when treating with hemp?

The attending physician, because dried flower is dispensed by prescription in category Rpw. The patient reports observations and symptoms, while the choice of pharmaceutical product remains a medical decision.

How long does the effect of dried flower last after vaporization, and how long after ingestion?

After vaporization, the first sensations appear after a few minutes, and the effects last for two to four hours. After ingestion, one waits from half an hour to two hours, and the episode can last six, sometimes eight hours.

Have adverse effects been described in studies on daytime strains?

No, because such studies do not exist. Reports are collected for the medicinal product with a batch number, and among the symptoms, dryness in the mouth, eye redness, and increased heart rate are the most common.

The material is for informational purposes only and does not replace medical advice or the content of the medicinal product leaflet.

Editorial text: ubocha.